CND Life Sciences to Highlight Momentum of Skin Biopsy Diagnostic Tool for Parkinson’s Disease and Related Disorders at the American Academy of Neurology 2024 Annual Meeting

– Synuclein-One Study plenary session on Monday, April 15 at 9:15 a.m. MT will report the detection of cutaneous phosphorylated alpha-synuclein in patients with dementia with Lewy bodies and mild cognitive impairment

– Multiple abstracts accepted, including one abstract of distinction, demonstrating the significance of using small skin biopsies in combination with advanced laboratory techniques to detect the misfolded protein that causes Parkinson’s disease and other synucleinopathies

SCOTTSDALE, Ariz.–(BUSINESS WIRE)–#DementiaWithLewyBodies—CND Life Sciences (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and associated biomarker services, today announced that six abstracts related to the identification of phosphorylated alpha-synuclein (P-SYN) in cutaneous nerve fibers in the skin will be presented at the American Academy of Neurology 2024 Annual Meeting (AAN) on April 13-18 in Denver at the Colorado Convention Center.

One abstract describes the first subgroup analysis from the Synuclein-One Study, an NIH-funded 30-site multicenter trial. The results are focused on patients with dementia with Lewy bodies (DLB) and mild cognitive impairment (MCI). This abstract was selected as a 2024 Abstract of Distinction based on the quality of the study and interest to the neurologic community and will be presented during the Contemporary Clinical Issues Plenary Session by Christopher Gibbons, MD, Senior Scientific Advisor and Co-Founder of CND Life Sciences and Professor of Neurology at Harvard Medical School on Monday, April 15 at 9:15 am MT.

A second abstract being presented describes the utility of the synuclein skin biopsy in the initial diagnosis and evaluation of Parkinsonian disorders in everyday clinical practice. This abstract will be presented during the Emerging Science 2 Session by Jonathan Ross Isaacson, MD, Neurophysiology Fellow at Beth Israel Deaconess Medical Center on Tuesday, April 16 at 5:36 p.m. MT.

Other abstracts include:

1. A single center retrospective review of essential tremor patients with a clinical phenotype of ‘Parkinsons plus’. The study focuses on patients demonstrating evidence of cutaneous phosphylated alpha-synucelin (P-SYN) deposition in the setting of normal dopamine transporter (DaTscans);
2. A study describing the utility of skin biopsy detection of P-SYN in patients with suspected drug-induced Parkinson’s with normal DaTscans;
3. A summary of patients with pure autonomic failure (PAF) from our Synuclein-One Study, an NIH-funded 30-site multicenter trial. PAF is a neurodegenerative disorder of the autonomic nervous system clinically characterized by orthostatic hypotension and commonly involving bladder and bowel dysfunction; and
4. A platform presentation unveiling CND’s groundbreaking NerValence™ technology that enables quantification of cutaneous phosphorylated alpha-synuclein using high resolution, high-throughput confocal imaging combined with artificial intelligence supported protein detection algorithms.

“All of the research that will be presented during AAN supports the groundbreaking diagnostic advances using skin biopsies to detect, quantify, and monitor neurodegenerative disease progression. As the population of neurodegenerative disease patients continues to grow, the need for accurate diagnostic tools is increasingly important to provide better care for patients,” said Dr. Gibbons.

“The demand for convenient, objective, and precise diagnostic tools and reliable biomarkers has never been greater, and the data presented at the AAN meeting will highlight our growing portfolio of work around the utility of our Syn-One Test^® through its potential to disrupt neurogenerative disease diagnoses and help biopharma companies move their scientific research forward,” said Todd Levine, MD, Chief Medical Officer of CND Life Sciences.

Details on relevant presentations are as follows:

About CND Life Sciences

CND Life Sciences supports the care of patients facing the potential diagnosis of a neurodegenerative disease and other neurological conditions. Operating a CLIA-certified and CAP-accredited laboratory in Scottsdale, Arizona, CND provides the Syn-One Test^® to clinicians and patients nationally as the world’s only commercially available test to detect, visualize, and quantify phosphorylated alpha-synuclein located in cutaneous nerves. The test uses small skin biopsies collected from the patient in a clinician’s office through a 15-minute minimally invasive procedure and includes an assessment of intraepidermal nerve fiber density and other important pathologic evaluations in the skin. The Company also collaborates with biopharmaceutical companies on clinical trials for investigational therapies targeting neurodegenerative diseases. Syn-One is supported by technology licensed from Beth Israel Deaconess Medical Center in Boston and has demonstrated high accuracy in detecting phosphorylated alpha-synuclein in patients with a suspected synucleinopathy including Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. CND has been awarded three prestigious NIH SBIR grants to advance the validation and clinical utility of its Syn-One Test, including assessing the test’s ability to provide early disease detection and prognostic insights. For more information, visit cndlifesciences.com or connect with us on LinkedIn.

SOURCE: CND Life Sciences

Disclosure: Research reported in this publication was supported by the National Institute of Neurological Disorders and Stroke and the National Institute on Aging (NIA) of the National Institutes of Health under Award Numbers R44NS117214, R44AG076072, and R44NS127696. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Contacts

Lisa DeScenza

LaVoieHealthScience

(978) 395-5970

ldescenza@lavoiehealthscience.com